The vaccine will be tested on 300 volunteers between the ages of six and 17. The role of children in the transmission of the coronavirus is still unclear.
With a new clinical study, researchers at Oxford University want to test whether the corona vaccine from the manufacturer AstraZeneca is also effective in children and adolescents. To do this, the drug, which the company and the university jointly developed, is to be tested on 300 volunteers between the ages of six and 17.
“It is important to study how children and adolescents react to the vaccine, as some children could benefit from vaccination,” said Andrew Pollard of Oxford University in a statement on Saturday. Most children would not get sick from the virus.
The first tests should start this month. Up to 240 test persons receive the vaccine, the rest, however, a control agent.
The vaccine, called ChAdOx1 nCoV-19, is based on certain engineered viruses that are actually found in monkeys and has been used in adults in the UK for weeks.
The UK Government’s deputy chief medical advisor, Jonathan Van-Tam, recently announced that several studies are currently underway to develop vaccines for children.
“Evidence that children are less likely to become infected”
According to the Royal College of Paediatrics and Child Health paediatricians’ association, Covid-19 can also lead to death or serious illness in children. But this is rare. It is clear that the mortality from Covid-19 in children is significantly lower than in the elderly. “
The re is also evidence that children are less likely to become infected.”
The role of children in the transmission is still unclear. However, there is no clear evidence that they are more contagious than adults.
Oxford expert Rinn Song said the pandemic has had a profound negative impact on education, social development and emotional well-being of children and adolescents. “It is therefore important to collect data on the safety and immune response to our corona vaccine in these age groups so that they may benefit from being included in vaccination programs in the near future.”
(WHAT / dpa)